E.‐M. Grischke

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Ulrike Nitz, Oleg Gluz, Matthias Christgen et al. · Annals of Oncology · 2017 · 172 citations

Medicine, Oncology, Pharmacology +17

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Predictive value of serum interleukin‐6 and ‐8 levels in preterm labor or rupture of the membranes

Gϋnter von Minckwitz, E.‐M. Grischke, STEFANIE SCHWAB et al. · Acta Obstetricia Et Gynecologica Scandinavica · 2000 · 70 citations · Full text

Medicine, Immunology, Obstetrics +17

EFFECTS OF LATE CORD CLAMPING ON CIRCULATION IN PREMATURES (VLBWI)

Mathias Nelle, Susan G. Fisher, S Conze et al. · Pediatric Research · 1998 · 39 citations

Medicine, Obstetrics, Hemodynamic Management +9